Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. SI-BONE, Inc.
  6. News
  7. Summary
    SIBN   US8257041090


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SI BONE : Reports Second Quarter 2021 Financial Results and Announces Exclusive Coverage from Anthem (Form 8-K)

08/03/2021 | 06:18am EDT
SI-BONE, Inc. Reports Second Quarter 2021 Financial Results and Announces Exclusive Coverage from Anthem

Record Second Quarter 2021 Worldwide Revenue of $22.2 million

SANTA CLARA, Calif. August 2, 2021 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended June 30, 2021.

Recent Highlights
•Record worldwide revenue of $22.2 million for the second quarter 2021, representing a 58% increase over the corresponding period in 2020 which was significantly impacted by COVID-19
•U.S. revenue of $20.2 million for the second quarter 2021, representing a 53% increase over the corresponding period in 2020
•Gross margin of 89% for the second quarter 2021
•Received exclusive coverage by Anthem, the second largest commercial health insurer in the U.S. with over 40 million members
•Received positive coverage by Centene Corporation, a major intermediary for both government-sponsored and privately insured health care programs with over 25 million members
•Published 2-year results from a prospective multi-center clinical trial of the iFuse-3D™ Implant System, the 95th peer-reviewed publication demonstrating the safety, effectiveness, biomechanical or economic benefits of iFuse Technology™

'Our strong performance in the quarter reaffirms the underlying strength of our business and growing demand for our innovative solutions,' said Laura Francis, Chief Executive Officer of SI-BONE. 'With the exclusive coverage from Anthem, substantially all of the U.S insured population now has access to minimally invasive SI joint fusion. As the recovery progresses and the operating environment continues to normalize, our planned investments across product innovation, sales force expansion, surgeon engagement and patient awareness position us to accelerate market expansion and further extend our leadership as a sacropelvic surgical solutions company.'

Second Quarter 2021 Financial Results

Worldwide revenue was $22.2 million in the second quarter 2021, a 58% increase from $14.0 million in the corresponding period in 2020. U.S. revenue for the second quarter 2021 was $20.2 million, a 53% increase from $13.2 million in the corresponding period in 2020. International revenue for the second quarter 2021 was $2.0 million, a 137% increase from $0.8 million in the corresponding period in 2020. The second quarter 2020 was significantly impacted by COVID-19.

Gross margin was 89% for the second quarter 2021, as compared to 85% in the corresponding period in 2020 as higher cost of operations to support the growth of the business were offset by lower inventory write-downs. The

second quarter 2020 gross margins were impacted by certain period costs that were expensed as incurred due to suboptimal capacity utilization driven by lower case volume and increases in inventory write-downs.

Operating expenses increased 49% to $32.8 million in the second quarter 2021, as compared to $22.1 million in the corresponding period in 2020. The higher operating expenses were driven by increased sales hiring, research and development expenses for new product development costs and increased stock-based compensation expense. The second quarter 2020 operating expenses were impacted by preemptive steps taken in response to COVID-19 to reduce discretionary spending.

Operating loss was $13.0 million in the second quarter 2021, as compared to an operating loss of $10.1 million in the corresponding period in 2020.

Net loss was $14.0 million, or $0.42 per diluted share for the second quarter 2021, as compared to a net loss of $12.5 million, or $0.44 per diluted share in the corresponding period in 2020.

Cash and marketable securities were $176.6 million and long-term borrowings were $39.6 million as of June 30, 2021.

2021 Financial Guidance

The Company continues to take a measured approach given the early stages of the COVID-19 recovery, and maintains the full year 2021 total revenue guidance to be approximately $92 million to $94 million, representing growth of 25% to 28% compared to full year 2020. Given the gross margin trends in the first and second quarter of 2021, the Company is updating the gross margin guidance to between 87% to 89% for full year 2021.

Webcast and Conference Call Information

SI-BONE will host a conference call to discuss the second quarter 2021 financial results after market close on Monday, August 2, 2021 at 4:30 P.M. Eastern Time. The conference call can be accessed live over the phone (866) 470-1968 for domestic callers or (409) 217-8248 for international callers, using conference ID: 4296117. The webcast can be accessed at https://investor.si-bone.com.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. In 2009, SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, shown to be a source of pain in 15% to 30% of chronic low back pain. Since then, more than 2,400 surgeons have performed a combined total of more than 55,000 SI joint fusion procedures. A unique body of evidence, supporting the iFuse Implant System, including two RCT's and over 95 peer reviewed publications, has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System. SI-BONE is leveraging its market leadership position, supported by this proprietary reimbursement advantage, to commercialize other devices intended for surgical treatment of related aspects of the human anatomy. For more information or to join our team, please visit us at www.si-bone.com.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved.

Forward Looking Statements

The statements in this press release regarding expectations of future events or results, including SI-BONE's expectations of continued growth and financial outlook, contained in this press release are 'forward-looking' statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve significant risks and uncertainties. These risks include the impact the COVID-19 pandemic will have on the ability and desire of patients and physicians to undergo procedures using the iFuse Implant System, the duration of the COVID-19 pandemic, the impact from the current and potential future variants of the COVID-19 virus, the pace of vaccination campaigns, impact from physician and patient vacations, pace of backlog replenishment, and SI-BONE's ability to increase demand for iFuse, and maintain favorable third-party payor coverage and reimbursement policies. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these and other risks and uncertainties, many of which are described in the company's most recent filings on Form 10-K and Form 10-Q, and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov), especially under the caption 'Risk Factors'. SI-BONE does not undertake any obligation to update forward-looking statements and expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.

Investor Contact
Matt Bacso, CFA

(In thousands, except share and per share amounts)
Three Months Ended
June 30,
Six Months Ended
June 30,
2021 2020 2021 2020
$ 22,194 $ 14,049 $ 42,636 $ 30,870
Cost of goods sold
2,375 2,117 4,575 4,049
Gross profit 19,819 11,932 38,061 26,821
Operating expenses:
Sales and marketing 23,084 15,755 44,006 35,036
Research and development 3,149 2,165 6,104 4,255
General and administrative 6,551 4,151 12,491 9,551
Total operating expenses
32,784 22,071 62,601 48,842
Loss from operations
(12,965) (10,139) (24,540) (22,021)
Interest and other income (expense), net:
Interest income 46 329 107 827
Interest expense (1,075) (2,683) (2,139) (3,914)
Other income (expense), net 13 21 349 (136)
Net loss
$ (13,981) $ (12,472) $ (26,223) $ (25,244)
Net loss per share, basic and diluted
$ (0.42) $ (0.44) $ (0.80) $ (0.91)
Weighted-average number of common shares used to compute basic and diluted net loss per share
32,978,914 28,492,582 32,836,040 27,872,505

(in thousands)
June 30, December 31,
2021 2020
Current assets:
Cash and cash equivalents $ 48,125 $ 53,581
Short-term investments 128,508 142,851
Accounts receivable, net 11,894 13,611
Inventory 8,151 5,633
Prepaid expenses and other current assets 2,434 2,565
Total current assets 199,112 218,241
Property and equipment, net 7,868 4,527
Other non-current assets 352 374
TOTAL ASSETS $ 207,332 $ 223,142
Current liabilities:
Accounts payable $ 3,918 $ 3,271
Accrued liabilities and other 8,706 10,199
Total current liabilities 12,624 13,470
Long-term borrowings 39,630 39,455
Other long-term liabilities 880 854
Stockholders' Equity:
Common stock and additional paid-in capital
419,238 408,116
Accumulated other comprehensive income 460 524
Accumulated deficit (265,500) (239,277)


SI-BONE Inc. published this content on 02 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 August 2021 09:57:43 UTC.

ę Publicnow 2021
All news about SI-BONE, INC.
10/11SI BONE : Announces UnitedHealthcare Adopts Exclusive iFuse Only Coverage for Minimally In..
08/23SI BONE : to Participate in Upcoming Conferences
08/13SI-BONE, INC. : Entry into a Material Definitive Agreement, Termination of a Material Defi..
08/13Si-Bone, Inc. Enters into A Loan and Security Agreement with Silicon Valley Bank., A Ca..
08/04SI BONE : Management's Discussion and Analysis of Financial Condition and Results of Opera..
08/03SI BONE : Reports Second Quarter 2021 Financial Results and Announces Exclusive Coverage f..
08/03SI BONE : Needham Adjusts SI-Bone's Price Target to $37 From $42; Buy Rating Kept
08/02SI-BONE : Q2 Earnings Snapshot
08/02SI-BONE, INC. : Results of Operations and Financial Condition, Financial Statements and Ex..
08/02Si-Bone, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
More news
Analyst Recommendations on SI-BONE, INC.
More recommendations
Financials (USD)
Sales 2021 93,1 M - -
Net income 2021 -52,2 M - -
Net cash 2021 104 M - -
P/E ratio 2021 -14,3x
Yield 2021 -
Capitalization 760 M 760 M -
EV / Sales 2021 7,05x
EV / Sales 2022 5,73x
Nbr of Employees 295
Free-Float 98,1%
Duration : Period :
SI-BONE, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SI-BONE, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 7
Last Close Price 22,85 $
Average target price 40,00 $
Spread / Average Target 75,1%
EPS Revisions
Managers and Directors
Laura A. Francis Chief Executive Officer & Director
Anshul Maheshwari Chief Financial & Accounting Officer
Jeffrey W. Dunn Executive Chairman
Scott A. Yerby Chief Technology Officer
W. Carlton Reckling Chief Medical Officer & VP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
SI-BONE, INC.-23.58%760
GETINGE AB94.85%11 840
PENUMBRA, INC.53.00%9 794
ASAHI INTECC CO., LTD.-21.70%7 013